- Home
- SENEA vs IMTX Comparison
SENEA vs IMTX Comparison
Compare SENEA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- IMTX
- Stock Information
- Founded
- SENEA 1949
- IMTX N/A
- Country
- SENEA United States
- IMTX Germany
- Employees
- SENEA N/A
- IMTX N/A
- Industry
- SENEA Packaged Foods
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SENEA Consumer Staples
- IMTX Health Care
- Exchange
- SENEA Nasdaq
- IMTX Nasdaq
- Market Cap
- SENEA 557.7M
- IMTX 559.1M
- IPO Year
- SENEA N/A
- IMTX N/A
- Fundamental
- Price
- SENEA $80.49
- IMTX $4.60
- Analyst Decision
- SENEA
- IMTX Strong Buy
- Analyst Count
- SENEA 0
- IMTX 4
- Target Price
- SENEA N/A
- IMTX $16.67
- AVG Volume (30 Days)
- SENEA 13.7K
- IMTX 1.2M
- Earning Date
- SENEA 02-06-2025
- IMTX 03-20-2025
- Dividend Yield
- SENEA N/A
- IMTX N/A
- EPS Growth
- SENEA 25.61
- IMTX N/A
- EPS
- SENEA 5.45
- IMTX N/A
- Revenue
- SENEA $1,541,031,000.00
- IMTX $128,824,447.00
- Revenue This Year
- SENEA N/A
- IMTX $116.22
- Revenue Next Year
- SENEA N/A
- IMTX N/A
- P/E Ratio
- SENEA $14.77
- IMTX N/A
- Revenue Growth
- SENEA 4.01
- IMTX 52.53
- 52 Week Low
- SENEA $46.56
- IMTX $4.48
- 52 Week High
- SENEA $81.45
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- SENEA 65.40
- IMTX 27.20
- Support Level
- SENEA $77.08
- IMTX $4.85
- Resistance Level
- SENEA $81.45
- IMTX $5.25
- Average True Range (ATR)
- SENEA 2.00
- IMTX 0.28
- MACD
- SENEA 0.54
- IMTX -0.01
- Stochastic Oscillator
- SENEA 90.83
- IMTX 8.96
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.